Copyright
©The Author(s) 2021.
World J Clin Cases. Dec 26, 2021; 9(36): 11285-11299
Published online Dec 26, 2021. doi: 10.12998/wjcc.v9.i36.11285
Published online Dec 26, 2021. doi: 10.12998/wjcc.v9.i36.11285
Table 4 Clinical course of all patients (Crohn’s disease + ulcerative colitis) (those who switched from infliximab originator are excluded), n (%)
| Active disease | Clinical remission | Clinical response | |
| Baseline (n = 201) | 138 (68.6) | - | - |
| 3 mo (n = 152) | 37 (24.4) | 81 (53.2) | 34 (22.3) |
| 6 mo (n = 122) | 21 (17.2) | 74 (60.7) | 27 (22.1) |
| 9 mo (n = 84) | 8 (9.5) | 61 (72.6) | 15 (17.9) |
| 12 mo (n = 81) | 12 (14.8) | 52 (64.2) | 17 (21) |
- Citation: Huguet JM, Cortés X, Bosca-Watts MM, Aguas M, Maroto N, Martí L, Amorós C, Paredes JM. Real-world data on the infliximab biosimilar CT-P13 (Remsima®) in inflammatory bowel disease. World J Clin Cases 2021; 9(36): 11285-11299
- URL: https://www.wjgnet.com/2307-8960/full/v9/i36/11285.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v9.i36.11285